Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
On October 10, 2023, Simcere Pharmaceutical Group Ltd. (2096.HK) announced that they entered into a collaboration agreement with Jiaxing AnDiCon Biotech Co., Ltd. (AnDiCon) on the anti-influenza innovative drug ADC189. Pursuant to the Agreement, Simcere Pharmaceutical obtains the exclusive commercialization rights of the drug ADC189 for treating influenza in China.
Shanghai Medicilon Inc. (Medicilon), as a partner of AnDiCon, is fortunate to undertake the formulation research and development of ADC189, witnessing AnDiCon’s solid steps in the field of respiratory anti-infection in China. AnDiCon and Simcere Pharmaceuticals have reached an authorization agreement for ADC189, which once again proves the therapeutic potential and advantages of this drug.
On October 10, 2023, the signing ceremony between Simcere Pharmaceuticals and AnDiCon
This collaboration on the exclusive commercialization rights of the innovative anti-influenza drug ADC189 will further enhance Simcere Pharmaceuticals’ product layout in the anti-infectious field and reflect the commercial synergy in the anti-infectious field. In the field of anti-infection, Simcere Pharmaceuticals has launched a number of products including Xiannuoxin, the first Chinese produced 3CL innovative anti-COVID-19 drug. The collaboration between AnDiCon and Simcere Pharmaceuticals will better achieve complementary advantages and win-win collaboration, and will bring Chinese wisdom and solutions that can “heal” and “reach” China’s public health security.
